Maintenance therapy in multiple myeloma: Two is not always better than one

In multiple myeloma (MM) long‐term therapy aims to control disease and delay progression for as long as possible. In this issue Jenner et al. failed to demonstrate a benefit of maintenance with lenalidomide plus vorinostat compared with lenalidomide in both transplant eligible (TE) and ineligible (N...

Full description

Saved in:
Bibliographic Details
Published in:British journal of haematology 2023-04, Vol.201 (2), p.181-182
Main Authors: Offidani, Massimo, Morè, Sonia, Corvatta, Laura
Format: Article
Language:English
Subjects:
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Dexamethasone - therapeutic use
Hematology
Humans
Lenalidomide - therapeutic use
maintenance
Multiple myeloma
Multiple Myeloma - therapy
Treatment Outcome
Vorinostat
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c3884-f795da9aeaf5ac007a67a8e4fc4d1ff8d6b07710d3f228a3e458e50ddedf89c53
cites cdi_FETCH-LOGICAL-c3884-f795da9aeaf5ac007a67a8e4fc4d1ff8d6b07710d3f228a3e458e50ddedf89c53
container_end_page 182
container_issue 2
container_start_page 181
container_title British journal of haematology
container_volume 201
creator Offidani, Massimo
Morè, Sonia
Corvatta, Laura
description In multiple myeloma (MM) long‐term therapy aims to control disease and delay progression for as long as possible. In this issue Jenner et al. failed to demonstrate a benefit of maintenance with lenalidomide plus vorinostat compared with lenalidomide in both transplant eligible (TE) and ineligible (NTE) patients enrolled in the Myeloma XI trial. Commentary on: Jenner et al. The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial. Br J Haematol. 2023;201:276‐288.
doi_str_mv 10.1111/bjh.18614
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2756672284</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2756672284</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3884-f795da9aeaf5ac007a67a8e4fc4d1ff8d6b07710d3f228a3e458e50ddedf89c53</originalsourceid><addsrcrecordid>eNp10D1PwzAQBmALgWgpDPwBZIkFhrR2YicuG1R8VUUsZY4uyVlNlTghTlTl3-OSwoDELbc89-r0EnLJ2ZS7mSXbzZSrkIsjMuZBKD2fC35MxoyxyONMqBE5s3bLGA-Y5Kdk5IzgPFBjsnyD3LRowKRI2w02UPc0N7TsijavC6Rlj0VVwh1d7yqaW2qqlkKxg97SBNsWG3cFhlYGz8mJhsLixWFPyMfT43rx4q3en18X9ysvDZQSno7mMoM5IGgJqfsQwggUCp2KjGutsjBhUcRZFmjfVxCgkAolyzLMtJqnMpiQmyG3bqrPDm0bl7lNsSjAYNXZ2I9kGEbuVjh6_Yduq64x7jun5tL3Qz_Yq9tBpU1lbYM6rpu8hKaPOYv3Bceu4Pi7YGevDoldUmL2K38adWA2gF1eYP9_UvywfBkivwCE-YQd</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2795226234</pqid></control><display><type>article</type><title>Maintenance therapy in multiple myeloma: Two is not always better than one</title><source>Wiley</source><creator>Offidani, Massimo ; Morè, Sonia ; Corvatta, Laura</creator><creatorcontrib>Offidani, Massimo ; Morè, Sonia ; Corvatta, Laura</creatorcontrib><description>In multiple myeloma (MM) long‐term therapy aims to control disease and delay progression for as long as possible. In this issue Jenner et al. failed to demonstrate a benefit of maintenance with lenalidomide plus vorinostat compared with lenalidomide in both transplant eligible (TE) and ineligible (NTE) patients enrolled in the Myeloma XI trial. Commentary on: Jenner et al. The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial. Br J Haematol. 2023;201:276‐288.</description><identifier>ISSN: 0007-1048</identifier><identifier>EISSN: 1365-2141</identifier><identifier>DOI: 10.1111/bjh.18614</identifier><identifier>PMID: 36541138</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Dexamethasone - therapeutic use ; Hematology ; Humans ; Lenalidomide - therapeutic use ; maintenance ; Multiple myeloma ; Multiple Myeloma - therapy ; Treatment Outcome ; Vorinostat</subject><ispartof>British journal of haematology, 2023-04, Vol.201 (2), p.181-182</ispartof><rights>2022 British Society for Haematology and John Wiley &amp; Sons Ltd.</rights><rights>2023 British Society for Haematology and John Wiley &amp; Sons Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3884-f795da9aeaf5ac007a67a8e4fc4d1ff8d6b07710d3f228a3e458e50ddedf89c53</citedby><cites>FETCH-LOGICAL-c3884-f795da9aeaf5ac007a67a8e4fc4d1ff8d6b07710d3f228a3e458e50ddedf89c53</cites><orcidid>0000-0003-2749-7347</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36541138$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Offidani, Massimo</creatorcontrib><creatorcontrib>Morè, Sonia</creatorcontrib><creatorcontrib>Corvatta, Laura</creatorcontrib><title>Maintenance therapy in multiple myeloma: Two is not always better than one</title><title>British journal of haematology</title><addtitle>Br J Haematol</addtitle><description>In multiple myeloma (MM) long‐term therapy aims to control disease and delay progression for as long as possible. In this issue Jenner et al. failed to demonstrate a benefit of maintenance with lenalidomide plus vorinostat compared with lenalidomide in both transplant eligible (TE) and ineligible (NTE) patients enrolled in the Myeloma XI trial. Commentary on: Jenner et al. The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial. Br J Haematol. 2023;201:276‐288.</description><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Dexamethasone - therapeutic use</subject><subject>Hematology</subject><subject>Humans</subject><subject>Lenalidomide - therapeutic use</subject><subject>maintenance</subject><subject>Multiple myeloma</subject><subject>Multiple Myeloma - therapy</subject><subject>Treatment Outcome</subject><subject>Vorinostat</subject><issn>0007-1048</issn><issn>1365-2141</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNp10D1PwzAQBmALgWgpDPwBZIkFhrR2YicuG1R8VUUsZY4uyVlNlTghTlTl3-OSwoDELbc89-r0EnLJ2ZS7mSXbzZSrkIsjMuZBKD2fC35MxoyxyONMqBE5s3bLGA-Y5Kdk5IzgPFBjsnyD3LRowKRI2w02UPc0N7TsijavC6Rlj0VVwh1d7yqaW2qqlkKxg97SBNsWG3cFhlYGz8mJhsLixWFPyMfT43rx4q3en18X9ysvDZQSno7mMoM5IGgJqfsQwggUCp2KjGutsjBhUcRZFmjfVxCgkAolyzLMtJqnMpiQmyG3bqrPDm0bl7lNsSjAYNXZ2I9kGEbuVjh6_Yduq64x7jun5tL3Qz_Yq9tBpU1lbYM6rpu8hKaPOYv3Bceu4Pi7YGevDoldUmL2K38adWA2gF1eYP9_UvywfBkivwCE-YQd</recordid><startdate>202304</startdate><enddate>202304</enddate><creator>Offidani, Massimo</creator><creator>Morè, Sonia</creator><creator>Corvatta, Laura</creator><general>Blackwell Publishing Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-2749-7347</orcidid></search><sort><creationdate>202304</creationdate><title>Maintenance therapy in multiple myeloma: Two is not always better than one</title><author>Offidani, Massimo ; Morè, Sonia ; Corvatta, Laura</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3884-f795da9aeaf5ac007a67a8e4fc4d1ff8d6b07710d3f228a3e458e50ddedf89c53</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Dexamethasone - therapeutic use</topic><topic>Hematology</topic><topic>Humans</topic><topic>Lenalidomide - therapeutic use</topic><topic>maintenance</topic><topic>Multiple myeloma</topic><topic>Multiple Myeloma - therapy</topic><topic>Treatment Outcome</topic><topic>Vorinostat</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Offidani, Massimo</creatorcontrib><creatorcontrib>Morè, Sonia</creatorcontrib><creatorcontrib>Corvatta, Laura</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of haematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Offidani, Massimo</au><au>Morè, Sonia</au><au>Corvatta, Laura</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Maintenance therapy in multiple myeloma: Two is not always better than one</atitle><jtitle>British journal of haematology</jtitle><addtitle>Br J Haematol</addtitle><date>2023-04</date><risdate>2023</risdate><volume>201</volume><issue>2</issue><spage>181</spage><epage>182</epage><pages>181-182</pages><issn>0007-1048</issn><eissn>1365-2141</eissn><abstract>In multiple myeloma (MM) long‐term therapy aims to control disease and delay progression for as long as possible. In this issue Jenner et al. failed to demonstrate a benefit of maintenance with lenalidomide plus vorinostat compared with lenalidomide in both transplant eligible (TE) and ineligible (NTE) patients enrolled in the Myeloma XI trial. Commentary on: Jenner et al. The addition of vorinostat to lenalidomide maintenance for patients with newly diagnosed multiple myeloma of all ages: results from ‘Myeloma XI’, a multicentre, open‐label, randomised, phase III trial. Br J Haematol. 2023;201:276‐288.</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>36541138</pmid><doi>10.1111/bjh.18614</doi><tpages>2</tpages><orcidid>https://orcid.org/0000-0003-2749-7347</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0007-1048
ispartof British journal of haematology, 2023-04, Vol.201 (2), p.181-182
issn 0007-1048
1365-2141
language eng
recordid cdi_proquest_miscellaneous_2756672284
source Wiley
subjects Antineoplastic Combined Chemotherapy Protocols - therapeutic use
Dexamethasone - therapeutic use
Hematology
Humans
Lenalidomide - therapeutic use
maintenance
Multiple myeloma
Multiple Myeloma - therapy
Treatment Outcome
Vorinostat
title Maintenance therapy in multiple myeloma: Two is not always better than one
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T05%3A21%3A57IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Maintenance%20therapy%20in%20multiple%20myeloma:%20Two%20is%20not%20always%20better%20than%20one&rft.jtitle=British%20journal%20of%20haematology&rft.au=Offidani,%20Massimo&rft.date=2023-04&rft.volume=201&rft.issue=2&rft.spage=181&rft.epage=182&rft.pages=181-182&rft.issn=0007-1048&rft.eissn=1365-2141&rft_id=info:doi/10.1111/bjh.18614&rft_dat=%3Cproquest_cross%3E2756672284%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3884-f795da9aeaf5ac007a67a8e4fc4d1ff8d6b07710d3f228a3e458e50ddedf89c53%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2795226234&rft_id=info:pmid/36541138&rfr_iscdi=true